Skip to main content

Advertisement

SpringerLink
Log in

Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory Urgency Urinary Incontinence)?

  • Overactive Bladder and Lower Urinary Tract Symptoms (U Lee and S Adelstein, Section Editors)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Overactive bladder (OAB) is highly prevalent with increasing age. Conservative management including lifestyle adaptation, controlled fluid intake, and bladder training are considered first-line therapeutic options. Second-line options are medication such as antimuscarinics or beta-3 adrenergic receptor agonists. Therapy refractory patients should be referred to a specialist for further evaluation.

Recent Findings

It currently remains unclear if patients should undergo routine urodynamic investigation (UDI) before offering third-line therapies like sacral neuromodulation (SNM) or intradetrusor injection of onabotulinumtoxinA (IdetInBotA). The aim of this narrative review was to assess if the presence of detrusor overactivity (DO) can predict treatment success of third-line therapies for OAB.

Summary

There is only limited evidence available for both IdetInBotA and SNM, but treatment success does not appear to be related to the presence of DO in baseline UDI. Hence, routine UDI is not mandatory in patients with OAB but remains an option when its outcome is likely to change the treatment strategy or to assess the risk of upper urinary tract deterioration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.

    Article  PubMed  Google Scholar 

  2. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4. https://doi.org/10.1002/nau.22609.

    Article  PubMed  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. https://doi.org/10.1007/s00345-002-0301-4.

    Article  PubMed  CAS  Google Scholar 

  4. •• Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018; https://doi.org/10.1016/j.eururo.2017.12.031. The current European reference for diagnosing and managing urinary incontinence.

  5. Rovner ES, Goudelocke CM. Urodynamics in the evaluation of overactive bladder. Curr Urol Rep. 2010;11(5):343–7. https://doi.org/10.1007/s11934-010-0130-8.

    Article  PubMed  Google Scholar 

  6. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 2003;62(5 Suppl 2):28–37. discussion 40-2

    Article  PubMed  Google Scholar 

  7. •• Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, et al. Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69(2):324–33. https://doi.org/10.1016/j.eururo.2015.07.071. The current European reference for diagnosing and managing lower urinary tract symptoms and dysfunction in patients with neurogenic disorders.

    Article  PubMed  Google Scholar 

  8. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22(2):105–8. https://doi.org/10.1002/nau.10099.

    Article  PubMed  Google Scholar 

  9. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175(1):191–4; discussion 4-5. https://doi.org/10.1016/s0022-5347(05)00067-4.

    Article  PubMed  CAS  Google Scholar 

  10. Lowenstein L, Pham T, Abbasy S, Kenton K, Brubaker L, Mueller ER, et al. Observations relating to urinary sensation during detrusor overactivity. Neurourol Urodyn. 2009;28(6):497–500. https://doi.org/10.1002/nau.20680.

    Article  PubMed  Google Scholar 

  11. Guralnick ML, Grimsby G, Liss M, Szabo A, O'Connor RC. Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. Int Urogynecol J. 2010;21(3):325–9. https://doi.org/10.1007/s00192-009-1030-7.

    Article  PubMed  Google Scholar 

  12. Hanna-Mitchell AT, Kashyap M, Chan WV, Andersson KE, Tannenbaum C. Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Neurourol Urodyn. 2014;33(5):611–7. https://doi.org/10.1002/nau.22582.

    Article  PubMed  CAS  Google Scholar 

  13. Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010;105(9):1268–75. https://doi.org/10.1111/j.1464-410X.2009.09037.x.

    Article  PubMed  CAS  Google Scholar 

  14. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 2009;103(7):931–7. https://doi.org/10.1111/j.1464-410X.2009.08361.x.

    Article  PubMed  Google Scholar 

  15. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556–62. https://doi.org/10.1002/nau.21021.

    Article  PubMed  CAS  Google Scholar 

  16. • Richter HE, Amundsen CL, Erickson SW, Jelovsek JE, Komesu Y, Chermansky C, et al. Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence. J Urol. 2017;198(4):890–6. https://doi.org/10.1016/j.juro.2017.04.103. An interesting analysis of prognostic factors for clinical response to onabotulinumtoxinA and sacral neuromodulation for refractory UUI.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. South MM, Romero AA, Jamison MG, Webster GD, Amundsen CL. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(12):1395–8. https://doi.org/10.1007/s00192-007-0351-7.

    Article  PubMed  Google Scholar 

  18. Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 2008;101(3):325–9. https://doi.org/10.1111/j.1464-410X.2007.07258.x.

    Article  PubMed  Google Scholar 

  19. Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6A Suppl):57–67. discussion 8-73

    Article  PubMed  CAS  Google Scholar 

  20. Vereecken RL, Das J. Urethral instability: related to stress and/or urge incontinence? J Urol. 1985;134(4):698–701.

    Article  PubMed  CAS  Google Scholar 

  21. Dokmeci F, Cetinkaya SE, Seval MM, Dai O. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle. Eur J Obstet Gynecol Reprod Biol. 2017;212:126–31. https://doi.org/10.1016/j.ejogrb.2017.03.023.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Inselspital, University of Bern, Bern, Switzerland

    Marc P. Schneider & Fiona C. Burkhard

  2. Department of Urology, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy

    Andrea Tubaro

Authors
  1. Marc P. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Tubaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fiona C. Burkhard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fiona C. Burkhard.

Ethics declarations

Conflict of Interest

Marc P. Schneider, Andrea Tubaro, and Fiona C. Burkhard declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Overactive Bladder and Lower Urinary Tract Symptoms

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schneider, M.P., Tubaro, A. & Burkhard, F.C. Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory Urgency Urinary Incontinence)?. Curr Bladder Dysfunct Rep 13, 158–161 (2018). https://doi.org/10.1007/s11884-018-0480-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-018-0480-5

Keywords

Search

Navigation